Wieneke A. Buikhuisen

Author

Also Known As

Buikhuisen, W., W A Buikhuisen, W Buikhuisen, W. A. Buikhuisen, W. Buikhuisen, W.A. Buikhuisen, Wieneke A Buikhuisen, Wieneke A. Buikhuisen, Wieneke Alexandra Buikhuisen, Wieneke Buikhuisen

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute University College London Institut Gustave Roussy Radboud University Nijmegen

About

Wieneke A. Buikhuisen is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.1K
2	Health Sciences	7	7	416
3	Cell Biology	2	2	288
4	Natural Sciences	1	1	139
5	Biochemistry	1	1	139

Wieneke A. Buikhuisen

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma Josine M.M.F. Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Journal of Thoracic Oncology	2018	244
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial Lee M. Krug, Hedy L. Kindler, Hilary Calvert, The Lancet Oncology Surgical OncologyMedicinePrevious ChemotherapyPleural DiseasePlacebo-controlled Trial	2015	219
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients Ekaterina A. Semenova, Min‐Chul Kwon, Kim Monkhorst, Cell Reports OncologyMedicineTumor GrowthTranscription Factor NfibPathology	2016	149
High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes. Barbara Haber, S Chin, Emil Chuang, Journal of Clinical Investigation Regenerating LiverGlucose HomeostasisCell CycleMetabolic RemodelingInsulin Signaling	1995	139
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial Piero Ferollà, Maria Pia Brizzi, Tim Meyer, The Lancet Oncology Long-acting PasireotideOncologyMedicineClinical TrialsPathology	2017	134
Clinical features of large cell neuroendocrine carcinoma: a population-based overview Jules L. Derks, Lizza Hendriks, Wieneke A. Buikhuisen, European Respiratory Journal Endocrine OncologyMedicineLcnec CasesNeuroendocrine DisorderAdjuvant Chemotherapy	2015	122
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study Wieneke A. Buikhuisen, Jacobus A. Burgers, Andrew Vincent, The Lancet Oncology Nvalt 5Surgical OncologyMedicineCancer ManagementActive Supportive Care	2013	97
Systematic and combined endosonographic staging of lung cancer (SCORE study) Laurence Crombag, Christophe Dooms, Jos A. Stigt, European Respiratory Journal	2018	85
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites Talya L. Dayton, Nicolas Alcala, Laura Moonen, Cancer Cell	2023	69
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies Josine M.M.F. Quispel-Janssen, Giulia Zago, Robert D. Schouten, Journal of Thoracic Oncology Malignant Pleural MesotheliomaMedicinePathologyTranslational ResearchPleural Disease	2017	52

Page 1